• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dementia and Geriatric Cognitive Disorders Extra >An Open-Label, Multicenter Observational Study for Patients with Alzheimer’s Disease Treated with Memantine in the Clinical Practice
【24h】

An Open-Label, Multicenter Observational Study for Patients with Alzheimer’s Disease Treated with Memantine in the Clinical Practice

机译：美金刚在临床实践中对阿尔茨海默氏病患者进行的开放标签，多中心观察性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aims: In this post-marketing observational study, the safety and effectiveness of memantine were evaluated in patients with Alzheimer’s disease (AD). Methods: In a 6-month, observational, open-label study at 202 specialist sites in Greece, the effectiveness of memantine was evaluated using the Mini-Mental State Examination (MMSE) and the Instrumental Activities of Daily Living (IADL) scale at baseline, and after 3 and 6 months. Discontinuation rates and adverse drug reactions (ADRs) were also recorded to evaluate the safety profile of memantine. Results: 2,570 patients participated in the study. Three and 6 months after baseline, MMSE and IADL scores were significantly improved compared to baseline. At the end of the study, 67% of the patients had improved their MMSE score; 7.1% of the patients reported ≧1 ADRs, and treatment was discontinued due to ADR in 0.7%. Conclusion: Memantine was well tolerated and had a positive effect on the patient’s cognitive and functional ability in real-life clinical practice, in agreement with randomized, controlled trials.
机译：背景/目的：在这项上市后的观察性研究中，评估了美金刚在阿尔茨海默氏病（AD）患者中的安全性和有效性。方法：在希腊的202个专业地点进行的为期6个月的开放性观察性研究中，使用最低精神状态检查（MMSE）和基线日常工具活动量（IADL）量表评估了美金刚的有效性，以及3个月和6个月之后。还记录了停药率和药物不良反应（ADR），以评估美金刚的安全性。结果：2570名患者参加了研究。基线后三个月和六个月，与基线相比，MMSE和IADL评分显着提高。在研究结束时，67％的患者的MMSE评分得到改善; 7.1％的患者报告了ADR≥1，并且由于0.7％的ADR而终止治疗。结论：与随机对照试验一致，美金刚胺在现实生活中具有良好的耐受性，并且对患者的认知和功能能力具有积极作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号